Characteristics and in-hospital outcomes of Chinese elderly (>80 years) patients with acute ischemic stroke receiving intravenous recombinant tissue plasminogen activator treatment within 4.5 hours of symptom onset (0135-0348)

Study identification

• EU PAS number:
  EUPAS41509
• Study ID:
  48061
• Official title and acronym:
  Characteristics and in-hospital outcomes of Chinese elderly (>80 years) patients with acute ischemic stroke receiving intravenous recombinant tissue plasminogen activator treatment within 4.5 hours of symptom onset (0135-0348)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  Alteplase in elderly AIS during hospitalization
• Study status:
  Planned

Research institutions and networks

Institutions

Beijing Tiantan Hospital

Study timelines

Date when funding contract was signed

Planned:30/09/2021

Actual:08/10/2021

Study start date

Planned:01/12/2022

Date of final study report

Planned:30/12/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable